-
1 Comment
Redx Pharma Plc is currently in a long term downtrend where the price is trading 11.4% below its 200 day moving average.
From a valuation standpoint, the stock is 95.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 20.2.
Redx Pharma Plc's total revenue sank by 0.0% to $2M since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-998K since the same quarter in the previous year.
Finally, its free cash flow grew by 787.6% to $2M since the same quarter in the previous year.
Based on the above factors, Redx Pharma Plc gets an overall score of 2/5.
| Exchange | LSE |
|---|---|
| CurrencyCode | GBP |
| ISIN | GB00BSNB6S51 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Beta | -0.53 |
|---|---|
| Market Cap | 58M |
| PE Ratio | None |
| Target Price | 130 |
| Dividend Yield | None |
Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating fibrotic disease, cancer, and the emerging area of cancer-associated fibrosis in the areas of unmet medical needs. The company also develops zelasudil (RXC007), a selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, which is in Phase 2 clinical trial for the treatment of multiple interstitial lung diseases and cancer-associated fibrosis; RXC008, a potential first-in-class GI-targeted ROCK inhibitor that is in preclinical studies for the treatment of fibrostenotic Crohn's disease; and zamaporvint (RXC004), a porcupine inhibitor that is in Phase 2 clinical trial for targeted therapy of Wnt-ligand dependent cancers. In addition, it is developing RXC009, a potent and selective DDR1 inhibitor, which is in preclinical studies for the treatment of chronic kidney disease; Kirsten rat sarcoma virus (KRAS) inhibitor to target G12D selective and multi-KRAS profiles; RXC006/AZD5055 a porcupine inhibitor, which is in Phase 1 clinical trial for targeting fibrotic diseases, including idiopathic pulmonary fibrosis; JZP815, a pan-rapidly accelerated fibrosarcoma inhibitor that is in Phase 1 clinical trial to overcome resistance mechanisms associated with clinically approved B-RAF selective drugs; and mitogen-activated protein kinase pathway targets for oncology indications. The company has research collaboration agreements with Jazz Pharmaceuticals plc to develop JZP815, as well as discovery and preclinical development of a targeted cancer therapy on the Ras/RAF/MAP kinase pathway; and AstraZeneca plc to develop RXC006/AZD5055, a Porcupine inhibitor for the treatment of fibrotic disease. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for REDX.LSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
